Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.87 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.87 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.87 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.87 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.87 |
| ▸ | ABL1 | P00519 | 6/20 | 0.87 |
| ▸ | INSR | P06213 | 6/20 | 0.87 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.87 |
| ▸ | CDK2 | P24941 | 6/20 | 0.87 |
| ▸ | PLK1 | P53350 | 6/20 | 0.87 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.87 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.87 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.87 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.87 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.87 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.87 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.87 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4006793 | 1.00 | EGFR (0.87) | EGFRERBB2HDAC1HDAC8HDAC6 | |
| SCHEMBL12795243 | 0.93 | EGFR (1.00) | EGFRERBB2HDAC1HDAC8HDAC6 | |
| SCHEMBL4006108 | 0.93 | EGFR (0.74) | EGFRERBB2HDAC1HDAC8HDAC6 | |
| SCHEMBL4006106 | 0.93 | EGFR (0.74) | EGFRERBB2HDAC1HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL3662960 | 0.92 | EGFR (0.97) | EGFRERBB2HDAC1HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL3662957 | 0.92 | EGFR (0.97) | EGFRERBB2HDAC1HDAC8HDAC6 | |
| SCHEMBL4005197 | 0.91 | EGFR (0.81) | EGFRERBB2HDAC1HDAC8HDAC6 | |
| SCHEMBL4005193 | 0.91 | EGFR (0.81) | EGFRERBB2HDAC1HDAC8HDAC6 | |
| SCHEMBL4087795 | 0.91 | EGFR (0.81) | EGFRERBB2HDAC1HDAC8HDAC6 | |
| SCHEMBL4087790 | 0.91 | EGFR (0.81) | EGFRERBB2HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065734-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | 4SC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2060565-A1 | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases | 4SC AG (DE) | 2009-05-20 | — | — | EP | disclosed |
| US-7507741-B2 | quinazoline derivatives; protein tyrosine kinase inhibitors, to treat various malignancies, Metabolic and proliferative disorders; 2-{{[5-(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-6-quinazolinyl)-2-furyl]methyl}[2-(methylsulfonyl)ethyl]amino}acetonitrile; side effects reduction; anticarcinogenic agent | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080004294-A1 | quinazoline derivatives; protein tyrosine kinase inhibitors, to treat various malignancies, Metabolic and proliferative disorders; 2-{{[5-(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-6-quinazolinyl)-2-furyl]methyl}[2-(methylsulfonyl)ethyl]amino}acetonitrile; side effects reduction; anticarcinogenic agent | COCKERILL GEORGE S | 2008-01-03 | — | — | US | disclosed |
| EP-1192151-B1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2007-11-07 | — | — | EP | disclosed |
| US-7265123-B2 | 4-Phenylaminopyrido[4,3-d]pyrimidines 6-heteroaryl-substituted, in which the heteroaryl is substituted with a sulfonylethylamino-, thio- or oxy- group; protein tyrosine kinase inhibitors, used especially to treat various malignancies | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070093512-A1 | 4-Phenylaminopyrido[4,3-d]pyrimidines 6-heteroaryl-substituted, in which the heteroaryl is substituted with a sulfonylethylamino-, thio- or oxy- group; protein tyrosine kinase inhibitors, used especially to treat various malignancies | COCKERILL GEORGE S | 2007-04-26 | — | — | US | disclosed |
| US-7189734-B2 | Anticancer agents; (4-(3-Fluorobenzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)ethyl)-thiazol-4-yl)-quinazolin-4-yl)-amine | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-20060189637-A1 | 4-Phenylaminopyrido[4,3-d]pyrimidines 6-heteroaryl-substituted, in which the heteroaryl is substituted with a sulfonylethylamino-, thio- or oxy- group; protein tyrosine kinase inhibitors, used especially to treat various malignancies | COCKERILL GEORGE S | 2006-08-24 | — | — | US | disclosed |
| US-7084147-B2 | Anticancer agents; (4-(3-Fluorobenzyloxy)-3-chlorophenyl)-(6-(2-((2-phenylsulphonyl-ethylamino)methyl)-thiazol-4-yl)-quinazolin-4-yl)-amine | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-01 | — | — | US | disclosed |
| US-6933299-B1 | Anilinoquinazolines as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050143401-A1 | Anticancer agents; (4-(3-Fluorobenzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)ethyl)-thiazol-4-yl)-quinazolin-4-yl)-amine | COCKERILL GEORGE S (GB) | 2005-06-30 | — | — | US | disclosed |
| EP-1192151-A1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001004111-A1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004294-A1 | quinazoline derivatives; protein tyrosine kinase inhibitors, to treat various malignancies, Metabolic and proliferative disorders; 2-{{[5-(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-6-quinazolinyl)-2-furyl]methyl}[2-(methylsulfonyl)ethyl]amino}acetonitrile; side effects reduction; anticarcinogenic agent | ABL1, CDK2, ERBB2 | EGFR 208/4885ERBB2 3/4885HDAC1 1555/4885 |
| US-20110065734-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | HDAC1, HDAC11, MAP2K2 | EGFR 1304/4885ERBB2 499/4885HDAC1 1/4885 |
| US-20060189637-A1 | 4-Phenylaminopyrido[4,3-d]pyrimidines 6-heteroaryl-substituted, in which the heteroaryl is substituted with a sulfonylethylamino-, thio- or oxy- group; protein tyrosine kinase inhibitors, used especially to treat various malignancies | ABL1, ERBB2, SRC | EGFR 105/4885ERBB2 2/4885HDAC1 2835/4885 |
| US-20050143401-A1 | Anticancer agents; (4-(3-Fluorobenzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)ethyl)-thiazol-4-yl)-quinazolin-4-yl)-amine | ABL1, ERBB2, ERBB4 | EGFR 71/4885ERBB2 2/4885HDAC1 1133/4885 |
| US-20070093512-A1 | 4-Phenylaminopyrido[4,3-d]pyrimidines 6-heteroaryl-substituted, in which the heteroaryl is substituted with a sulfonylethylamino-, thio- or oxy- group; protein tyrosine kinase inhibitors, used especially to treat various malignancies | ABL1, ERBB2, SRC | EGFR 105/4885ERBB2 2/4885HDAC1 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.